.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AC04_InsulinLispro.InsulinLispro_1 .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AC04_InsulinLispro.InsulinLispro_1| name: | InsulinLispro_1 |
| ATC code: | A10AC04_1 | route: | subcutaneous |
| n-compartments | 2 |
Insulin lispro is a rapid-acting human insulin analog used for glycemic control in diabetes mellitus. It acts quickly to lower blood glucose and is approved for medical use.
Pharmacokinetic parameters for adult patients with type 1 diabetes after subcutaneous injection.
de la Peña, A, et al., & Ignaut, DA (2015). Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects. Journal of diabetes science and technology 9(4) 824–830. DOI:10.1177/1932296815573865 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25697717
Chao, M, et al., & Ning, G (2010). Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. Endocrine 38(1) 48–52. DOI:10.1007/s12020-010-9326-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20960101
Shiramoto, M, et al., & Ohwaki, K (2020). Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog. Journal of diabetes investigation 11(3) 672–680. DOI:10.1111/jdi.13195 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31816193